Celgene Corporation (NASDAQ: CELG) shares plummeted 10 percent Tuesday evening after the U.S. Food and Drug Administration rejected its New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis. (benzinga.com)
Celgene Corporation (NASDAQ: CELG) is under continued stock pressure Wednesday after the U.S. Food and Drug Administration rejected its New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis. (benzinga.com)
It acquired Receptos last year for $ 7.2 billion, gaining hold of promising experimental multiple sclerosis and ulcerative colitis drug ozanimod in the process. (fool.com)